Rhythm Pharmaceuticals Inc
Chiusa
SettoreSettore sanitario
89.31 1.35
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
88.12
Massimo
96.82
Entrata | -8.1M -56M |
|---|---|
Vendite | 2.9M 60M |
EPS | -0.83 |
Margine di Profitto | -92.559 |
Dipendenti | 414 |
EBITDA | -9.7M -52M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +56.71% upside |
Utili prossimi | 4 ago 2026 |
|---|
Capitalizzazione di Mercato | 126M 6B |
|---|---|
Apertura precedente | 87.96 |
Chiusura precedente | 89.31 |
Notizie sul Sentiment di mercato
By Acuity
25%
75%
62 / 342 Classifica in Healthcare
Rhythm Pharmaceuticals Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.